Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T02703 | ||||
Target Name | Nitric-oxide synthase inducible (NOS2) | ||||
Type of Target |
Clinical trial |
||||
Drug Potency against Target | Hydrocortisone | Drug Info | IC50 = 5 microM | [17] | |
Drug Info | Ki = 570 nM | [15] | |||
((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine | Drug Info | IC50 = 890 nM | [1] | ||
(4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 130 nM | [2] | ||
(4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 150 nM | [2] | ||
(4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 6800 nM | [2] | ||
(4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 56 nM | [2] | ||
(4S,5S)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 2500 nM | [2] | ||
(5-Imino-[1,4]thiazepan-3-yl)-methanol | Drug Info | IC50 = 1100 nM | [4] | ||
(5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine | Drug Info | IC50 = 528 nM | [5] | ||
(5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine | Drug Info | IC50 = 186 nM | [5] | ||
(E)-4-Methyl-6-(prop-1-enyl)pyridin-2-amine | Drug Info | IC50 = 282 nM | [13] | ||
(R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 1200 nM | [4] | ||
(S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid | Drug Info | IC50 = 14000 nM | [16] | ||
(S)-2-Amino-6-[(E)-ethylimino]-hexanoic acid | Drug Info | IC50 = 4600 nM | [16] | ||
(S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 190 nM | [4] | ||
(S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid | Drug Info | IC50 = 2100 nM | [4] | ||
(S)-N-(1-phenylethyl)acetimidamide hydrobromide | Drug Info | IC50 = 450 nM | [14] | ||
1-(6-Amino-4-methylpyridin-2-yl)propan-2-ol | Drug Info | IC50 = 1776 nM | [13] | ||
1400W | Drug Info | IC50 = 330 nM | [14] | ||
2-(2-Amino-ethyl)-7-imino-azepane | Drug Info | IC50 = 701 nM | [1] | ||
2-amino-4-methylpyridine | Drug Info | IC50 = 120 nM | [11] | ||
2-Amino-5-(N-nitro-guanidino)-pentanoic acid | Drug Info | IC50 = 7600 nM | [16] | ||
2-Aminothiazoline | Drug Info | IC50 = 900 nM | [3] | ||
2-Methyl-[1,4]thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 3500 nM | [4] | ||
3,4-Dihydro-1H-quinolin-(2E)-ylideneamine | Drug Info | IC50 = 14000 nM | [5] | ||
3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 1200 nM | [3] | ||
3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane | Drug Info | IC50 = 6660 nM | [1] | ||
3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine | Drug Info | IC50 = 979 nM | [1] | ||
3-Bromo-1H-indazole-7-carbonitrile | Drug Info | IC50 = 5700 nM | [10] | ||
3-Butyl-[1,4]oxazepan-(5Z)-ylideneamine | Drug Info | IC50 = 2430 nM | [1] | ||
3-Butyl-[1,4]thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 500 nM | [4] | ||
3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 310 nM | [4] | ||
3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 320 nM | [4] | ||
3-Methyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 1500 nM | [3] | ||
3-Methyl-[1,4]thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 810 nM | [4] | ||
3-Propyl-[1,4]thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 290 nM | [4] | ||
4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 300 nM | [3] | ||
4-Butyl-thiazolidin-(2E)-ylideneamine | Drug Info | IC50 = 5200 nM | [3] | ||
4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 930 nM | [3] | ||
4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 160 nM | [3] | ||
4-Ethyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 1600 nM | [2] | ||
4-Ethyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 500 nM | [3] | ||
4-Isopropyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 3500 nM | [3] | ||
4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 2000 nM | [3] | ||
4-Methyl-6-(2-methylprop-1-enyl)pyridin-2-amine | Drug Info | IC50 = 685 nM | [13] | ||
4-methyl-6-propylpyridin-2-amine | Drug Info | IC50 = 15 nM | [11] | ||
4-Methyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 1500 nM | [2] | ||
4-Methyl-piperidin-(2E)-ylideneamine | Drug Info | IC50 = 37 nM | [5] | ||
4-Methyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 200 nM | [3] | ||
4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine | Drug Info | IC50 = 12000 nM | [14] | ||
5-Bromomethyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 500 nM | [2] | ||
5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 20 nM | [3] | ||
5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 10200 nM | [3] | ||
5-Ethyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 280 nM | [2] | ||
5-Methyl-4-propyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 13100 nM | [3] | ||
5-Methyl-oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 74 nM | [2] | ||
5-Methyl-pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 1300 nM | [3] | ||
6-(2-Fluoropropyl)-4-methylpyridin-2-amine | Drug Info | IC50 = 220 nM | [13] | ||
6-(3-Fluoropropyl)-4-methylpyridin-2-amine | Drug Info | IC50 = 57.6 nM | [13] | ||
6-(4-Fluorobutyl)-4-methylpyridin-2-amine | Drug Info | IC50 = 170 nM | [13] | ||
6-isobutyl-4-methylpyridin-2-amine | Drug Info | IC50 = 28 nM | [13] | ||
7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine | Drug Info | IC50 = 152 nM | [1] | ||
7-Butyl-azepan-(2Z)-ylideneamine | Drug Info | IC50 = 517 nM | [1] | ||
7-Methyl-[1,4]thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 3000 nM | [4] | ||
Aminothiazoline | Drug Info | IC50 = 18000 nM | [12] | ||
AR-C102222 | Drug Info | IC50 = 900 nM | [11] | ||
AR-C133057XX | Drug Info | IC50 = 1900 nM | [11] | ||
Azepan-(2Z)-ylideneamine | Drug Info | IC50 = 2060 nM | [1] | ||
Azocan-(2Z)-ylideneamine | Drug Info | IC50 = 9980 nM | [1] | ||
Azonan-(2Z)-ylideneamine | Drug Info | IC50 = 9800 nM | [16] | ||
CDDO | Drug Info | IC50 = 0.2 nM | [6] | ||
Curcumin | Drug Info | IC50 = 6000 nM | [9] | ||
Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine | Drug Info | IC50 = 3100 nM | [3] | ||
L-NIL | Drug Info | IC50 = 280 nM | [8] | ||
N-(5-Amino-6-oxo-heptyl)-acetamidine | Drug Info | IC50 = 2100 nM | [3] | ||
N-benzylacetimidamide hydrobromide | Drug Info | IC50 = 200 nM | [14] | ||
Octahydro-isoindol-(1Z)-ylideneamine | Drug Info | IC50 = 1200 nM | [3] | ||
ONO-1714 | Drug Info | IC50 = 3 nM | [2] | ||
Oxazolidin-(2Z)-ylideneamine | Drug Info | IC50 = 7900 nM | [2] | ||
Piperidin-(2E)-ylideneamine | Drug Info | IC50 = 300 nM | [5] | ||
Pyrrolidin-(2Z)-ylideneamine | Drug Info | IC50 = 4100 nM | [3] | ||
THIOCITRULLINE | Drug Info | IC50 = 300 nM | [7] | ||
[1,3]Oxazinan-(2E)-ylideneamine | Drug Info | IC50 = 1800 nM | [16] | ||
[1,3]Thiazinan-(2E)-ylideneamine | Drug Info | IC50 = 2900 nM | [16] | ||
[1,4]Oxazepan-(3E)-ylideneamine | Drug Info | IC50 = 160 nM | [4] | ||
[1,4]Oxazepan-(5E)-ylideneamine | Drug Info | IC50 = 11800 nM | [4] | ||
[1,4]Thiazepan-(3E)-ylideneamine | Drug Info | IC50 = 1200 nM | [4] | ||
[1,4]Thiazepan-(5E)-ylideneamine | Drug Info | IC50 = 1400 nM | [4] | ||
[1,5]Thiazocan-(4E)-ylideneamine | Drug Info | IC50 = 13100 nM | [1] | ||
References | |||||
REF 1 | Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. | ||||
REF 2 | 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. | ||||
REF 3 | Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. | ||||
REF 4 | Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. | ||||
REF 5 | Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. | ||||
REF 6 | Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg Med Chem Lett. 2005 May 2;15(9):2215-9. | ||||
REF 7 | Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2881-5. | ||||
REF 8 | Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43. | ||||
REF 9 | A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. | ||||
REF 10 | Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem. 2008 Jun 1;16(11):5962-73. | ||||
REF 11 | Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. | ||||
REF 12 | The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6206-9. | ||||
REF 13 | Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. | ||||
REF 14 | N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9. | ||||
REF 15 | Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives. J Med Chem. 2010 Nov 11;53(21):7804-24. | ||||
REF 16 | 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. | ||||
REF 17 | The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7926-30. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.